LLY Stock Jumps on Strong Earnings and Foundayo Hype, But Pricing Pressure Persists

What happened

Eli Lilly shares surged this week after reporting Q1'26 revenue of $19.8 billion, up 56% year-over-year, driven by Mounjaro and Zepbound sales and the FDA approval of oral obesity drug Foundayo. However, the filing reveals that volume growth of 65% was partially offset by a 13% consolidated price decline, with both key drugs benefiting from favorable one-time rebate adjustments. The market is celebrating the top-line beat and Foundayo's potential, but the pricing trajectory and reliance on adjustments indicate structural gross-to-net deterioration that the current valuation does not discount. With Mounjaro and Zepbound now comprising 65% of revenue, any payer pushback or slower oral uptake could compress earnings multiples from the current 34x P/E. The stock's jump appears to be a short-term reaction to headline momentum rather than a fundamental improvement in net pricing power, reinforcing the need for a cautious stance.

Implication

The core thesis remains on hold; the stock's rally lacks durable pricing support, and the bear case of structurally lower net prices remains live. Investors should monitor quarterly pricing disclosures and Foundayo uptake for signs of sustainable volume-driven growth without further gross-to-net erosion.

Thesis delta

The DeepValue master report already warned of pricing risks; this week's earnings beat and Foundayo approval do not change the underlying price deterioration. The market's bullish interpretation overlooks the one-time nature of adjustments and the ongoing erosion in realized prices, which keeps the risk-reward unfavorable at current levels. The WAIT rating remains appropriate.